Simulations Plus, Inc. (SLP)
Automate Your Wheel Strategy on SLP
With Tiblio's Option Bot, you can configure your own wheel strategy including SLP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SLP
- Rev/Share 3.9092
- Book/Share 9.4317
- PB 2.973
- Debt/Equity 0.0042
- CurrentRatio 4.3681
- ROIC 0.0159
- MktCap 563912440.0
- FreeCF/Share 0.4931
- PFCF 56.9091
- PE 78.0823
- Debt/Assets 0.004
- DivYield 0.0021
- ROE 0.0391
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
SLP Advances Predictive Toxicology With DILIsym 11: Shares to Benefit?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Simulations Plus unveils DILIsym 11, an upgraded version of its flagship QST platform to advance predictive toxicology and pediatric liver assessment safety.
Read More
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
Published: April 21, 2025 by: Business Wire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the i.
Read More
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
Published: April 11, 2025 by: Benzinga
Sentiment: Neutral
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Read More
Simulations Plus: I See Promising Growth, But I'm Staying Neutral
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Positive
Simulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and promising pipeline expansions, operational inefficiencies and rising costs raise concerns about near-term profitability. Management's ability to convert backlog into profitable revenue and stabilize margins is crucial for long-term shareholder value.
Read More
SLP's Q2 Earnings Top, Sales Up Y/Y Despite Industry Headwinds
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Simulations Plus' fiscal Q2 2025 performance gains from its strong software solutions and services portfolio amid limited customer funding.
Read More
Simulations Plus, Inc. (SLP) Q2 2025 Earnings Call Transcript
Published: April 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2025 Earnings Conference Call April 3, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & COO Conference Call Participants David Larsen - BTIG Scott Schoenhaus - KeyBanc Capital Markets Matt Hewitt - Craig-Hallum Christine Rains - William Blair Jeff Garro - Stephens Constantine Davies - Citizen Operator Greetings, and welcome to the Simulations Plus Second Quarter Fiscal 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Read More
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
Published: March 20, 2025 by: Business Wire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discu.
Read More
About Simulations Plus, Inc. (SLP)
- IPO Date 1997-06-18
- Website https://www.simulations-plus.com
- Industry Medical - Healthcare Information Services
- CEO Mr. John Anthony DiBella M.S.
- Employees 243